Legend

Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.

 Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. WHO TDR completed PhaseIII trials of rectal artesunate.

WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.  

* For children 13 – 60 months

** For infants 3 – 12 months

Brand names:

1 Coartem® Dispersible
2 Artesun® 
3 Eurartesim®
4 Pyramax® tablets or granules
5 ASAQ Winthrop® 
6 SPAQ-CO^TM

Target Product Profiles - represented by coloured bar(s) under the project box

____  3-day cure, artemisinin-based combination therapies  

____  Combinations aiming at a new single-exposure radical cure, TPP-1

____  Severe malaria treatment and pre-referral intervention

____  Intermittent /seasonal malaria chemoprevention 

____  Products targeting prevention of relapse for P. vivax 

Target Candidate Profiles- represented by icons

 Asexual blood stages

 Relapse prevention

 Transmission reduction

 Chemoprotection